Latest News
Neurogene Inc.
- Neurogene Inc. Estimates – NASDAQ:NGNE
- Neurogene to present NGN-401 gene therapy program differentiators at European congress
- Prudential Financial Inc. Opens New Position in Neurogene Inc. (NGNE) With 2.23 Million Share Purchase
- JENNISON ASSOCIATES LLC Adds 1,710,500 Shares of Neurogene Inc (NGNE)
- JPMorgan initiates Neurogene stock rating at Overweight on gene therapy potential
- Neurogene stock a new Overweight at J.P. Morgan (NGNE:NASDAQ)
- JPMorgan rates Neurogene overweight with $60 target citing NGN-401
- Prudential reports a passive Neurogene (NGNE) stake spanning more than 2 million shares.
Headlines from the last 30 days, linking to the original publishers. See all market news →